117 related articles for article (PubMed ID: 26637925)
1. Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer.
Spaks A; Jaunalksne I; Spaka I; Chudasama D; Pirtnieks A; Krievins D
Anticancer Res; 2015 Dec; 35(12):6979-83. PubMed ID: 26637925
[TBL] [Abstract][Full Text] [Related]
2. CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment.
Spaks A; Svirina D; Spaka I; Jaunalksne I; Breiva D; Tracums I; Krievins D
Biomarkers; 2016 Jul; 21(5):474-8. PubMed ID: 27098116
[TBL] [Abstract][Full Text] [Related]
3. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
4. Role of CXC group chemokines in lung cancer development and progression.
Spaks A
J Thorac Dis; 2017 Apr; 9(Suppl 3):S164-S171. PubMed ID: 28446981
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
6. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.
Chen X; Wang X; He H; Liu Z; Hu JF; Li W
PLoS One; 2015; 10(5):e0126276. PubMed ID: 25996878
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
[TBL] [Abstract][Full Text] [Related]
8. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case-control study.
Zimmermann M; Nickl S; Lambers C; Hacker S; Mitterbauer A; Hoetzenecker K; Rozsas A; Ostoros G; Laszlo V; Hofbauer H; Renyi-Vamos F; Klepetko W; Dome B; Ankersmit HJ
Clin Chim Acta; 2012 Jul; 413(13-14):1115-20. PubMed ID: 22465083
[TBL] [Abstract][Full Text] [Related]
9. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer.
Sheu CC; Yu YP; Tsai JR; Chang MY; Lin SR; Hwang JJ; Chong IW
Int J Cancer; 2006 Sep; 119(6):1419-26. PubMed ID: 16642481
[TBL] [Abstract][Full Text] [Related]
10. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
11. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis.
Liu W; Yang J; Chi PD; Zheng X; Dai SQ; Chen H; Xu BL; Liu WL
Int J Tuberc Lung Dis; 2013 Oct; 17(10):1346-53. PubMed ID: 24025389
[TBL] [Abstract][Full Text] [Related]
14. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.
Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318
[TBL] [Abstract][Full Text] [Related]
15. [Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis
and Prognosis of Stage I-II Non-small Cell Lung Cancer].
Liu Y; Wang X; Wang T; Zhang C; Zhang K; Zang R; Zhi X; Zhang W; Sun K
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):207-15. PubMed ID: 27118648
[TBL] [Abstract][Full Text] [Related]
16. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.
van der Drift MA; Hol BE; Klaassen CH; Prinsen CF; van Aarssen YA; Donders R; van der Stappen JW; Dekhuijzen PN; van der Heijden HF; Thunnissen FB
Lung Cancer; 2010 May; 68(2):283-7. PubMed ID: 19632736
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)].
Huang F; Wang XL; Geng Y; Li MX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):507-9. PubMed ID: 15989803
[TBL] [Abstract][Full Text] [Related]
18. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
19. Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study.
Ye S; Chen X; Yao Y; Li Y; Sun R; Zeng H; Shu Y; Yin H
Sci Rep; 2019 Feb; 9(1):2652. PubMed ID: 30804354
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
